Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf, allogeneic T-cell immunotherapies targeting infectious diseases, oncology indications, and neurological conditions. The company completed its SPAC business combination in 2023, transitioning to a publicly traded entity in the healthcare and life sciences sector. Its August 2023 Form 10-Q filing with the SEC reflects its status as a recently merged public company navigating early post-combination reporting requirements. Tevogen Bio's pipeline centers on its proprietary T-cell therapy platform, which the company positions as a scalable approach to precision immunotherapy. For comprehensive SPAC deal history, financials, and real-time filing alerts on TVGN and hundreds of other SPAC-related issuers, sign up for full data access at SpacDesk.